These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 9327252)

  • 21. In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp.
    Higa F; Arakaki N; Tateyama M; Koide M; Shinzato T; Kawakami K; Saito A
    J Antimicrob Chemother; 2003 Dec; 52(6):920-4. PubMed ID: 14613952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of resistance to erythromycin, rifampicin and ciprofloxacin in 98 clinical isolates of Legionella pneumophila.
    Onody C; Matsiota-Bernard P; Nauciel C
    J Antimicrob Chemother; 1997 Jun; 39(6):815-6. PubMed ID: 9222053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species.
    Higa F; Akamine M; Haranaga S; Tohyama M; Shinzato T; Tateyama M; Koide M; Saito A; Fujita J
    J Antimicrob Chemother; 2005 Dec; 56(6):1053-7. PubMed ID: 16260445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Legionella pneumonia caused by Legionella pneumophila serogroup 2: second case report in Japan.
    Furugen M; Koide M; Baba M; Sato Y; Teruya H; Naha Y; Tamayose M; Akamine M; Uchihara T; Atsumi E; Haranaga S; Yara S; Higa F; Tateyama M; Fujita J
    J Infect Chemother; 2008 Apr; 14(2):161-5. PubMed ID: 18622682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila.
    Edelstein PH; Hu B; Edelstein MA
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2533-5. PubMed ID: 15917565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of lomefloxacin (NY-198 or SC 47111), ciprofloxacin, and erythromycin against 100 clinical Legionella strains.
    Edelstein PH; Gaudet EA; Edelstein MA
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):93S-95S. PubMed ID: 2791505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of Legionnaires' disease.
    Dedicoat M; Venkatesan P
    J Antimicrob Chemother; 1999 Jun; 43(6):747-52. PubMed ID: 10404312
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibiotic susceptibility of Legionella pneumophila strains isolated in England and Wales 2007-17.
    Wilson RE; Hill RLR; Chalker VJ; Mentasti M; Ready D
    J Antimicrob Chemother; 2018 Oct; 73(10):2757-2761. PubMed ID: 30053025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents.
    Kitsukawa K; Hara J; Saito A
    J Antimicrob Chemother; 1991 Mar; 27(3):343-53. PubMed ID: 2037540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo activities of sparfloxacin in Legionella infections.
    Saito A; Gaja M
    Drugs; 1995; 49 Suppl 2():250-2. PubMed ID: 8549320
    [No Abstract]   [Full Text] [Related]  

  • 31. In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia.
    Edelstein PH; Edelstein MA; Lehr KH; Ren J
    J Antimicrob Chemother; 1996 Jan; 37(1):117-26. PubMed ID: 8647752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic Resistance and Azithromycin Resistance Mechanism of Legionella pneumophila Serogroup 1 in China.
    Jia X; Ren H; Nie X; Li Y; Li J; Qin T
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro activity of quinolones and macrolides against mycobacteria.
    Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
    J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan.
    Miyashita N; Kobayashi I; Higa F; Aoki Y; Kikuchi T; Seki M; Tateda K; Maki N; Uchino K; Ogasawara K; Kurachi S; Ishikawa T; Ishimura Y; Kanesaka I; Kiyota H; Watanabe A
    J Infect Chemother; 2018 May; 24(5):325-329. PubMed ID: 29459000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of lomefloxacin (SC 47111 or NY-198) against isolates of Legionella spp.
    Dubois J; Joly JR
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):89S-91S. PubMed ID: 2791504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation.
    Marco F; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 1997 Sep; 29(1):55-7. PubMed ID: 9350417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wild-type MIC distribution and epidemiological cut-off values in clinical Legionella pneumophila serogroup 1 isolates.
    Bruin JP; Ijzerman EP; den Boer JW; Mouton JW; Diederen BM
    Diagn Microbiol Infect Dis; 2012 Jan; 72(1):103-8. PubMed ID: 22100012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Typing of Legionella isolates during an epidemiological investigation can be helpful but also misleading: an example from Greece.
    Velonakis EN; Uldum SA; Giakoupi P; Loukoussias S; Nielsen SS; Spala G; Vatopoulos A
    Euro Surveill; 2006 Aug; 11(8):E060824.4. PubMed ID: 16966790
    [No Abstract]   [Full Text] [Related]  

  • 39. Antimicrobial activities of two investigational fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates.
    Gooding BB; Erwin ME; Barrett MS; Johnson DM; Jones RN
    Antimicrob Agents Chemother; 1992 Sep; 36(9):2049-50. PubMed ID: 1329642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic variation amongst genotypically homogeneous Legionella pneumophila serogroup 1 isolates: implications for the investigation of outbreaks of Legionnaires' disease.
    Harrison TG; Saunders NA; Haththotuwa A; Hallas G; Birtles RJ; Taylor AG
    Epidemiol Infect; 1990 Apr; 104(2):171-80. PubMed ID: 1969803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.